ALK and gastric cancer: Therefore, based on an actionable fusion frequency ≥0.5%, a clinically relevant response rate to ALK TKIs, and marginal additional cost when incorporated into existing comprehensive NGS workflows, we advocate routine ALK fusion assessment in all cases of metastatic or refractory gastric cancer.